BMC Biotechnology · 2011 · 19 citations · 53 references
Life SciencesCell BiologyMolecular BiologyApoptosisGene ExpressionGene TherapyApoptosis RegulationApoptotic SignalingCell DeathProgrammed Cell DeathApoptosis In Viral InfectionBid ActivationPro-apoptotic EffectorsPro-apoptotic ProteinsSuicide InhibitionTransgene ExpressionViral Induced ApoptosisViral Regulatory Proteins
BACKGROUND: Regulated expression of suicide genes is a powerful tool to eliminate specific subsets of cells and will find widespread usage in both basic and applied science. A promising example is the specific elimination of human immunodeficiency virus type 1 (HIV-1) infected cells by LTR-driven suicide genes. The success of this approach, however, depends on a fast and effective suicide gene, which is expressed exclusively in HIV-1 infected cells. These preconditions have not yet been completely fulfilled and, thus, success of suicide approaches has been limited so far. We tested truncated Bid (tBid), a human pro-apoptotic protein that induces apoptosis very rapidly and efficiently, as suicide gene for gene therapy against HIV-1 infection. RESULTS: When tBid was introduced into the HIV-1 LTR-based, Tat- and Rev-dependent transgene expression vector pLRed(INS)2R, very efficient induction of apoptosis was observed within 24 hours, but only in the presence of both HIV-1 regulatory proteins Tat and Rev. Induction of apoptosis was not observed in their absence. Cells containing this vector rapidly died when transfected with plasmids containing full-length viral genomic DNA, completely eliminating the chance for HIV-1 replication. Viral replication was also strongly reduced when cells were infected with HIV-1 particles. CONCLUSIONS: This suicide vector has the potential to establish a safe and effective gene therapy approach to exclusively eliminate HIV-1 infected cells before infectious virus particles are released.
53
Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis
Honglin Li, Hong Zhu, Chi-jie Xu et al. · Cell · 1998 · 4.4K citations · Full text
BID: a novel BH3 domain-only death agonist.
Kai Wang, Xiaoming Yin, Debra T. Chao et al. · Genes & Development · 1996 · 962 citations · Full text